Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders, Major Depressive Disorder is Suspected to Have the Greatest Burden by 2030,Kynurenine Pathway is Major Route Through Which the Essential Amino Acid Tryptophan is Metabolised and Activated in Time of Stress and Immune Activation.

Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07771517

Enrollment

Registered

2026-08-18

Start date

2027-03-14

Completion date

2029-05-20

Last updated

2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder (MDD)

Keywords

Kynurenine pathway, MDD, Kynurenine pathway in depressive disorders, Depressive disorder, Bipolar disorder, Role of kynurenine pathway and its Metabolites in depressive disorders

Brief summary

This is a case control study including simple random cases of 90 persons, 45 of them have depressive disorders and the other 45 are healthy individuals,age group between 18-60 years old, cases will be recruited from outpatient psychiatric clinic in sohag university hospital, all cases will be exposed to psychological assessment and also laboratory assessment of kynurenine metabolites by using biokits

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* age group 18: 60 years old * cases are drug free of at least 4 months

Exclusion criteria

* patients with comorbid other psychiatric disorders( SUD,anxiety) * patients with IQ below 90 * patients with psychotic features * patients with postpartum depression * patients with chronic medical illness that might affect immune function * patients under treatment with immune modulating therapy

Design outcomes

Primary

Measure	Time frame	Description
Psychological assessment of patients with depressive disorders	From the enrollment of all cases till three months later	All cases will be subjected to psychological assessment by using structured clinical interview for DSM-V to assess major depressive disorder,bipolar and other depressivedisorders, Hamilton depression rating scale HAN-D to assess MDD, Hamilton anxiety inventory HAM-A to assess anxiety disorders, Montreal cognitive assessment to assess cognitive functions, Pittsburg sleep quality index to assess quality of sleep and detailed family history will be obtained to assess possibility of genetic factors in health relatives to patients with depressive disorders.
Detect abnormalities in kynurenine pathway in patients with depressive disorders	From the time of enrollment till 3 months later	Blood samples will be collected from patients and healthy control cases in microbiology laboratory in Sohag university hospital; by using biokits for kynurenine to measure kynurenine level in nanomolar to low micromolar in liter, Add a tryptophan measure outcome to measure tryptophan level in micromol per liter Add a quinolinic acid measure outcome to measure quinolinic acid level in microgram per milliliter by ELISA

Outcome results